Comparison of two different steroid treatments... (2016 study) Skip to main content
RCT Eur Arch Otorhinolaryngol 2016

Comparison of two different steroid treatments with hyperbaric oxygen for idiopathic sudden sensorineural hearing loss

Sevil E, Bercin S, Muderris T, Gul F, Kiris M, Eur Arch Otorhinolaryngol, 2016

Tier 1, Curated

Manually reviewed and included in the Canada Hyperbarics research database.

Summary

What Researchers Did

Researchers compared two hyperbaric oxygen therapy protocols, one paired with steroid injections into the middle ear and one paired with intravenous steroids, for treating sudden hearing loss of unknown cause.

What They Found

This prospective trial of 80 patients divided into mild-to-moderate, severe, and profound hearing loss groups found mixed results that depended on severity. In mild-to-moderate patients, the intratympanic plus HBO group had a 78.9% success rate versus 70.5% for intravenous plus HBO. In severe patients, intratympanic plus HBO had an 81.8% success rate versus 58.2% for intravenous plus HBO. In profound patients, the result reversed: intratympanic plus HBO had a 40% success rate versus 72.7% for intravenous plus HBO.

What This Means for Canadian Patients

For sudden sensorineural hearing loss, this abstract does not report which steroid-delivery method is better overall, since the two protocols traded places depending on how severe the hearing loss was. Patients considering steroid and hyperbaric oxygen combination treatment would need to discuss with their care team which protocol fits their specific degree of hearing loss.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The abstract does not report statistical testing to confirm whether the differences between groups were significant, and the reversal of results in the profound hearing loss group suggests these findings may reflect small subgroup sizes rather than a reliable treatment effect.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type RCT
Category Sudden Hearing Loss
Source Pubmed
PubMed ID 26538427
Year Published 2016
Journal Eur Arch Otorhinolaryngol
MeSH Terms Adult; Audiometry, Pure-Tone; Combined Modality Therapy; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Routes; Ear, Middle; Female; Glucocorticoids; Hearing Loss, Sensorineural; Hearing Loss, Sudden; Humans; Hyperbaric Oxygenation; Male; Methylprednisolone; Middle Aged; Severity of Illness Index; Treatment Outcome

Cite This Study

Share

This study relates to Sudden Sensorineural Hearing Loss. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Sudden Hearing Loss

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: March 19, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology